GRI Bio Inc. Common Stock (GRI)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I have spent decades looking for businesses with durable competitive advantages, honest accounting, and a margin of safety. GRI Bio is a clinical-stage biopharmaceutical company with three employees, no reported revenue, and no profits in the last four years. Its lead candidate, GRI-0621, is in phase IIa for severe fibrotic lung diseases. That is a lottery ticket, not a moat. In fiscal 2025, the year ended 2025-12-31, GRI reported a net loss of $12.0M and diluted EPS of -$121.80. In fiscal 2024, net loss was $8.2M and diluted EPS -$1545.55; in fiscal 2023, net loss $13.0M and diluted EPS -$5018.09. More recently, in fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $1.6M and diluted EPS -$0.91, after a $2.0M loss in fiscal Q1 2026. FairStock's trailing free cash flow is -$10.4M, a -307.5% yield against a $3.4M market cap at the 2026-10-13 close. The Piotroski F-Score is 1/9 and Altman Z-Score is -3.88, warning of financial distress. The balance sheet shows no debt (D/E 0.00), and P/B is 0.33, but book value in a cash-burning biotech can vanish. P/E is -0.55, ROE -142.02%, so earnings-based value is meaningless. A 52-week range of $1.36 to $64.12 screams speculation. Without revenue or profits, I cannot call this a sound value investment. It may be an option on clinical data, but not a business with a margin of safety.

In plain English: GRI Bio is a very small healthcare company trying to develop new medicines for lung and immune diseases. It has no product sales and has lost money for years, so the business looks very weak and early-stage. The stock price is low, but because there are no profits or revenue, it does not look like a normal cheap bargain; it looks more like a risky bet on future test results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer